Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P10 versus MabThera plus CVP in advanced follicular lymphoma
2011-002813-12Phase 3Terminated
- Sponsor
- Celltrion
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Celltrion. Primary endpoint: Complete response rate. Started Sep 2011; status: terminated.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2011-002813-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002813-12.